The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · May 2014
Randomized Controlled Trial Multicenter StudyObesity and adiposity indicators, asthma, and atopy in Puerto Rican children.
Whether adiposity indicators other than body mass index (BMI) should be used in studies of childhood asthma is largely unknown. The role of atopy in "obese asthma" is also unclear. ⋯ Adiposity indicators are associated with asthma, asthma severity/control, and atopy in Puerto Rican children. Atopy significantly mediates the effect of adiposity on asthma outcomes. Longitudinal studies are needed to further investigate the causal role, if any, of adiposity distribution and atopy on "obese asthma" in childhood.
-
J. Allergy Clin. Immunol. · Apr 2014
Randomized Controlled Trial Multicenter Study Clinical TrialEfficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial.
Approximately 5% to 10% of asthmatic patients achieve incomplete symptom control on current therapies. The association of IL-13 with asthma pathology and reduced corticosteroid sensitivity suggests a potential benefit of anti-IL-13 therapy in refractory asthma. GSK679586, a humanized mAb, inhibits IL-13 binding to both IL-13 receptor α1 and α2. ⋯ Although well tolerated, GSK679586 did not demonstrate clinically meaningful improvements in asthma control, pulmonary function, or exacerbations in patients with severe asthma. Further studies are needed to determine whether therapies targeting IL-13, the functionally related IL-4 cytokine, or both can provide clinical benefit in patients with severe refractory asthma or a subpopulation of these patients beyond that achievable with high-dose corticosteroids.
-
J. Allergy Clin. Immunol. · Apr 2014
Randomized Controlled TrialGuselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis.
IL-23 expression is increased in psoriatic lesions and might regulate TH17 T-cell counts in patients with psoriasis. ⋯ IL-23 inhibition with a single dose of guselkumab results in clinical responses in patients with moderate-to-severe psoriasis, suggesting that neutralization of IL-23 alone is a promising therapy for psoriasis.
-
J. Allergy Clin. Immunol. · Dec 2013
Randomized Controlled TrialBronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma.
Bronchial thermoplasty (BT) has previously been shown to improve asthma control out to 2 years in patients with severe persistent asthma. ⋯ These data demonstrate the 5-year durability of the benefits of BT with regard to both asthma control (based on maintained reduction in severe exacerbations and ED visits for respiratory symptoms) and safety. BT has become an important addition to our treatment armamentarium and should be considered for patients with severe persistent asthma who remain symptomatic despite taking inhaled corticosteroids and long-acting β₂-agonists.
-
J. Allergy Clin. Immunol. · Nov 2013
Randomized Controlled Trial Multicenter StudyEffects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia.
Many asthmatic patients exhibit sputum eosinophilia associated with exacerbations. Benralizumab targets eosinophils by binding IL-5 receptor α, inducing apoptosis through antibody-dependent cell-mediated cytotoxicity. ⋯ Single-dose intravenous and multiple-dose subcutaneous benralizumab reduced eosinophil counts in airway mucosa/submucosa and sputum and suppressed eosinophil counts in bone marrow and peripheral blood. The safety profile supports further development. Additional studies are needed to assess the clinical benefit in asthmatic patients.